An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD

Phase 3

Completed

• Conditions: Macular Degeneration; Maculopathy, Age-Related

• Registration Number: NCT00058994
• Lead Sponsor: Alcon Research

Brief Summary

The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-03
• Study First Submitted: 2003-04-15
• Study First Submitted QC: 2003-04-15
• Study First Posted: 2003-04-16
• Primary Completion: 2006-11
• Study Completion: 2006-11
• Status Verified: 2008-08
• Last Update Submitted: 2012-11-28
• Last Update Posted: 2012-11-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (1)

South America; 🇺🇸 Fort Worth, Texas, United States